

Supplemental Appendix for:  
Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia  
Kelly Irwin et al.

### **APPENDIX S1. Summary of Guideline-Concordant for Breast Cancer Care**

#### Screening

- Screening mammogram < two years prior to diagnosis for women age > 42

#### Diagnosis and staging

- Documentation of hormone receptor status and Her-2/neu status (after 2006)
- Sentinel lymph node biopsy (patients age < 70 with Stage I-III disease)

#### Treatment

##### A. Stage I-III

- a. All patients
  - i. Surgery
    1. Lumpectomy or mastectomy (patient preference)
    2. Surgery within 90 days of diagnosis
  - ii. Radiation
    1. Post-lumpectomy: Invasive (Stage I-III) cancers unless age > 70
    2. Post-mastectomy: All node-positive disease and T3 disease after 2000
    3. Radiation within 12 weeks of surgery or chemotherapy
- b. ER/PR +, Her-2/neu negative patients
  - i. Endocrine therapy
    1. All patients
    2. Endocrine therapy < one year after diagnosis
  - ii. Chemotherapy
    1. All node-positive patients age < 70
    2. Chemotherapy within 120 days
- c. ER/PR+, Her-2/neu + patients
  - i. Chemotherapy
    1. Tumor size > 1cm
  - ii. Trastuzumab
    1. All patients
    2. Trastuzumab < one year after diagnosis (after 2006)
- d. Triple negative patients (ER/PR negative, Her-2/neu negative)
  - i. Chemotherapy
    1. All patients with tumor size > 1cm or node-positive disease
    2. Chemotherapy < 120 days after diagnosis

##### B. Stage IV

- a. ER/PR+ patients
  - i. Endocrine therapy
    1. All patients